Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP): a Randomized Double Blind Placebo Controlled Phase II Study
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Chronic sinusitis; Rhinosinusitis
- Focus Therapeutic Use
- Acronyms CRSsNP
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 31 Mar 2025 to 30 Sep 2025.
- 17 Apr 2025 Planned primary completion date changed from 31 Mar 2025 to 30 Sep 2025.
- 17 Apr 2025 Status changed from recruiting to active, no longer recruiting.